MEMPHIS, Tenn. -- (BUSINESS WIRE) -- GTx, Inc. (NASDAQ: GTXI) announced today that new preclinical data will be presented indicating that AKR1C3, a steroidogenic enzyme, is an androgen receptor-selective coactivator and promoter of growth in prostate cancer cells and castration resistant prostate cancer (CRPC), and may represent the first nuclear hormone receptor coactivator that can be pharmacologically targeted in the treatment of advanced prostate cancer. The presentation will be given by Dr. Ramesh Narayanan, Director, Drug Discovery for GTx, Inc. on February 14 at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in Orlando, Florida.
CRPC may occur by several mechanisms, including up-regulation of the androgen receptor, coactivators and steroidogenic enzymes, including AKR1C3. In vitro cellular and molecular biological techniques and novel AKR1C3-selective inhibitors developed by GTx facilitated the identification of AKR1C3 as a unique androgen receptor-selective coactivator that promotes prostate cancer growth. Over expression of AKR1C3 promotes both androgen-dependent prostate cancer and CRPC growth with concomitant reactivation of androgen signaling in xenograft models. The coactivator and growth promoting functions of AKR1C3 were inhibited by a novel AKR1C3-selective, competitive inhibitor developed by GTx.
Permanent Abstract ID: 100
Session Title: General Poster Session A: Prostate Cancer
Date: Thursday, February 14, 2013
Time: 11:45AM - 1:15PM
Location: Gatlin Ballroom B
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care and other serious medical conditions.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx’s drug discovery programs. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2012 contains under the heading, "Risk Factors", a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.